Conversation with The Cancer LetterCOVID-19 & CancerFree Stephen Nimer: Cancer patients are coming in for treatment, Florida’s COVID-19 spike notwithstanding July 31, 2020Vol.46 No.31By Paul Goldberg
COVID-19 & CancerFreeGuest Editorial The COVID challenge: Maintaining progress in multiple myeloma clinical investigation July 31, 2020Vol.46 No.31By Hearn Jay Cho
Trials & Tribulations Assessing the impact of the CMS price transparency rule on patients with prostate cancer July 24, 2020Vol.46 No.30By Ankit Agarwal and Trevor J. Royce
COVID-19 & CancerFreeLetter To The Editor Insurers’ moves to limit telehealth amid COVID-19 are inhumane and must be stopped July 24, 2020Vol.46 No.30
COVID-19 & Cancer Lowy: COVID-19 pandemic inspired new “shortcuts” in NCI clinical trials July 24, 2020Vol.46 No.30By Alexandria Carolan
American Cancer Society staff given seven days to vacate the National Home Office July 24, 2020Vol.46 No.30By Paul Goldberg
COVID-19 & Cancer NCI steps in to pay trainees whose funding from nonprofits fails to materialize July 24, 2020Vol.46 No.30By Alexandria Carolan
Conversation with The Cancer Letter Jason Hafron: A major wake-up call to U.S. medicine to administer androgen deprivation therapy for prostate cancer on time July 24, 2020Vol.46 No.30By Matthew Bin Han Ong
Prostate cancer patients aren’t getting testosterone suppression injections on timePayment policies blamed for non-compliance with treatment guidelines July 24, 2020Vol.46 No.30By Matthew Bin Han Ong
ODAC votes Yes on advanced multiple myeloma agent with ocular toxicity July 17, 2020Vol.46 No.29By Paul Goldberg
